The Grunenthal Group is science-based pharmaceutical company specialized in pain, gout and inflammation.

Grunenthal announced that Adhesys Medical GmbH, a wholly-owned subsidiary of the Grunenthal Group, has received CE-Certification for MAR-CUTIS (Flix®).

Flix® is a topical skin adhesive for surgical use and the first product from Grunenthal's innovative pipeline of surgical sealants. 

Grunenthal acquired Adhesys Medical GmbH and its US affiliate, a medical device start-up, in April 2017 and holds the worldwide development and commercialization rights for an innovative pipeline of surgical sealants and the underlying technology platform.

The polyurethane-based technology is unique, as it comes with an unmet combination of features such as bonding strength, fast sealing and flexibility.

The products based on this technology may therefore serve a wide variety of surgical procedures, including sealing in wet environments and allow Grunenthal to tap into the global surgical sealants market.

With devices and technologies like surgical sealants, the company broadens their portfolio beyond the development of new chemical entities (NCEs) in focus areas of high unmet medical need that is pain and inflammation.